According to the International Forum for the Study of Itch (IFSI), chronic pruritus can be classified into three categories. The etiological classification of pruritus on primarily non-lesional (IFSI II) skin can be challenging, particularly as many patients with internal medicine conditions suffer from accompanying pruritic symptoms. Practical guidance for a structured approach and a current overview of pathophysiological insights as well as topical and systemic therapeutic options are provided by the recently updated European guideline by interdisciplinary pruritus experts, which contains numerous evidence-based recommendations.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
- Bezafibrate
- biliary tract diseases
- Bylvay
- chronic pruritus
- Difelikefalin
- European guideline
- evidence-based recommendations
- gabapentin
- IFSI
- IFSI II
- internal medicine conditions
- International Forum for the Study of Itch
- Kidneys
- Liver
- Montelukast
- Nalbuphin
- Naltrexone
- Odevixibat
- pruritus experts
- pruritus on primarily non-lesional
- Sertraline
You May Also Like
- Disorders of the Gut-Brain Interaction
Rome V Criteria: What Has Changed, and What Has Remained the Same?
- Tourette Syndrome
What can be done to treat this tic disorder?
- Chronic Hepatitis B: Is a Cure in Sight?
Phase III Trial of Temporary Treatment with Bepirovirsen Was Successful
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Tumors of the Calcaneus
Diagnostic Challenges of Rare Heel Tumors
- Upper GI Tract Bleeding: Hematemesis, Hematochezia, or Melena?